TY - JOUR
T1 - Patterns of Current Cigarette Smoking, Quit Attempts and Cessation Counseling among Survivors of Smoking-Related and Nonsmoking-Related Urological Malignancies
T2 - A Nationally Representative Cross-Sectional Analysis
AU - Matulewicz, Richard S.
AU - Basak, Ramsankar
AU - Zambrano, Ibardo
AU - Dearing, Bianca A.
AU - Schatz, Daniel
AU - El Shahawy, Omar
AU - Sherman, Scott
AU - Bjurlin, Marc A.
N1 - Funding Information:
Supported by the New York State Department of Health Empire Clinical Research Investigator Program (ECRIP) (BAD, DS, OE, SS, and MAB) and a Linbeberger Comprehnesive Cancer Center Innovation Award and NC TraCS grant 550KR221903 (MAB).
Publisher Copyright:
© 2021 Lippincott Williams and Wilkins. All rights reserved.
PY - 2021/5/1
Y1 - 2021/5/1
N2 - Purpose:Cigarette smoking is the leading modifiable risk factor for several genitourinary malignancies. Although smoking cessation after genitourinary cancer diagnosis is a critical component of survivorship, factors related to continued smoking are under studied.Materials and Methods:A cross-sectional analysis was conducted using data from the National Health Interview Survey (2014-2018). Our primary study outcome was the prevalence and correlates of cigarette smoking among adults with a history of smoking-related (kidney or bladder) urological cancer compared to a nonsmoking-related control (prostate cancer). We used regression analyses to assess the association of having a smoking-related genitourinary cancer history with continued cigarette smoking after diagnosis. Secondary outcomes were yearly smoking trends, quit attempts and reported receipt of smoking cessation counseling.Results:A total of 2,664 respondents reported a history of genitourinary cancer, representing weighted estimates of 990,820 (smoking-related genitourinary cancer) and 2,616,596 (prostate cancer) adults. Survivors of smoking-related genitourinary cancers had a significantly higher overall prevalence of current cigarette use (14.8% vs 8.6%, p <0.001) and also reported more frequent receipt of counseling (79.8% vs 66.2%, p=0.02) but did not attempt to quit any more often than those with prostate cancer (52.4% vs 47.2%, p=0.44). Time trends demonstrated stable and persistent cigarette use among survivors of all genitourinary cancers. After adjustment for sociodemographic confounders, cancer type was not associated with current cigarette smoking (OR 1.23, 95% CI 0.86-1.77). However, older age and more advanced educational attainment were associated with lower odds of current cigarette smoking, while single marital status was associated with higher odds.Conclusions:In this population-based cross-sectional study of survivors of genitourinary cancers, those with a reported smoking-related genitourinary cancer had a higher prevalence of current cigarette smoking compared to those with prostate cancer, our nonsmoking-related control. Those with smoking-related genitourinary cancers reported more frequent receipt of smoking cessation counseling.
AB - Purpose:Cigarette smoking is the leading modifiable risk factor for several genitourinary malignancies. Although smoking cessation after genitourinary cancer diagnosis is a critical component of survivorship, factors related to continued smoking are under studied.Materials and Methods:A cross-sectional analysis was conducted using data from the National Health Interview Survey (2014-2018). Our primary study outcome was the prevalence and correlates of cigarette smoking among adults with a history of smoking-related (kidney or bladder) urological cancer compared to a nonsmoking-related control (prostate cancer). We used regression analyses to assess the association of having a smoking-related genitourinary cancer history with continued cigarette smoking after diagnosis. Secondary outcomes were yearly smoking trends, quit attempts and reported receipt of smoking cessation counseling.Results:A total of 2,664 respondents reported a history of genitourinary cancer, representing weighted estimates of 990,820 (smoking-related genitourinary cancer) and 2,616,596 (prostate cancer) adults. Survivors of smoking-related genitourinary cancers had a significantly higher overall prevalence of current cigarette use (14.8% vs 8.6%, p <0.001) and also reported more frequent receipt of counseling (79.8% vs 66.2%, p=0.02) but did not attempt to quit any more often than those with prostate cancer (52.4% vs 47.2%, p=0.44). Time trends demonstrated stable and persistent cigarette use among survivors of all genitourinary cancers. After adjustment for sociodemographic confounders, cancer type was not associated with current cigarette smoking (OR 1.23, 95% CI 0.86-1.77). However, older age and more advanced educational attainment were associated with lower odds of current cigarette smoking, while single marital status was associated with higher odds.Conclusions:In this population-based cross-sectional study of survivors of genitourinary cancers, those with a reported smoking-related genitourinary cancer had a higher prevalence of current cigarette smoking compared to those with prostate cancer, our nonsmoking-related control. Those with smoking-related genitourinary cancers reported more frequent receipt of smoking cessation counseling.
KW - neoplasms
KW - smoking
KW - smoking cessation
KW - tobacco products
KW - urology
KW - Kidney Neoplasms/etiology
KW - Cross-Sectional Studies
KW - Humans
KW - Middle Aged
KW - Cancer Survivors/statistics & numerical data
KW - Male
KW - Directive Counseling
KW - Prostatic Neoplasms/etiology
KW - Young Adult
KW - Cigarette Smoking/adverse effects
KW - Adolescent
KW - Aged, 80 and over
KW - Smoking Cessation/statistics & numerical data
KW - Adult
KW - Aged
KW - Urinary Bladder Neoplasms/etiology
UR - http://www.scopus.com/inward/record.url?scp=85105760744&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85105760744&partnerID=8YFLogxK
U2 - 10.1097/JU.0000000000001483
DO - 10.1097/JU.0000000000001483
M3 - Article
C2 - 33347778
AN - SCOPUS:85105760744
SN - 0022-5347
VL - 205
SP - 1444
EP - 1450
JO - Investigative Urology
JF - Investigative Urology
IS - 5
ER -